PortfoliosLab logoPortfoliosLab logo
KYMR vs. NVDA
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

KYMR vs. NVDA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Kymera Therapeutics, Inc. (KYMR) and NVIDIA Corporation (NVDA). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, KYMR achieves a 41.88% return, which is significantly higher than NVDA's 9.26% return.


KYMR

1D
-7.50%
1M
28.07%
6M
51.05%
YTD
41.88%
1Y
148.20%
3Y*
70.84%
5Y*
18.22%
10Y*

NVDA

1D
-3.52%
1M
-0.81%
6M
10.19%
YTD
9.26%
1Y
23.58%
3Y*
64.91%
5Y*
59.41%
10Y*
65.86%
*Multi-year figures are annualized to reflect compound growth (CAGR)

KYMR vs. NVDA - Yearly Performance Comparison


2026 (YTD)202520242023202220212020
KYMR
Kymera Therapeutics, Inc.
41.88%93.41%58.01%2.00%-60.69%2.40%77.14%
NVDA
NVIDIA Corporation
9.26%38.92%171.25%239.02%-50.26%125.48%7.59%

Correlation

The correlation between KYMR and NVDA is 0.14, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.14

Correlation (3Y)
Calculated over the trailing 3-year period

0.20

Correlation (5Y)
Calculated over the trailing 5-year period

0.30

Correlation (All Time)
Calculated using the full available price history since Aug 21, 2020

0.27

The correlation between KYMR and NVDA shifts across timeframes, from 0.14 (1 year) to 0.30 (5 years), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap

KYMR:

$9.08B

NVDA:

$4.93T

EPS

KYMR:

-$3.51

NVDA:

$6.53

PS Ratio

KYMR:

192.51

NVDA:

19.64

PB Ratio

KYMR:

6.99

NVDA:

25.40

Total Revenue (TTM)

KYMR:

$51.47M

NVDA:

$253.49B

Gross Profit (TTM)

KYMR:

$17.10M

NVDA:

$187.95B

EBITDA (TTM)

KYMR:

-$323.05M

NVDA:

$192.76B

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

KYMR vs. NVDA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

KYMR
KYMR Risk / Return Rank: 9494
Overall Rank
KYMR Sharpe Ratio Rank: 9494
Sharpe Ratio Rank
KYMR Sortino Ratio Rank: 9595
Sortino Ratio Rank
KYMR Omega Ratio Rank: 9393
Omega Ratio Rank
KYMR Calmar Ratio Rank: 9595
Calmar Ratio Rank
KYMR Martin Ratio Rank: 9393
Martin Ratio Rank

NVDA
NVDA Risk / Return Rank: 6565
Overall Rank
NVDA Sharpe Ratio Rank: 6767
Sharpe Ratio Rank
NVDA Sortino Ratio Rank: 6363
Sortino Ratio Rank
NVDA Omega Ratio Rank: 6060
Omega Ratio Rank
NVDA Calmar Ratio Rank: 6969
Calmar Ratio Rank
NVDA Martin Ratio Rank: 6868
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

KYMR vs. NVDA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Kymera Therapeutics, Inc. (KYMR) and NVIDIA Corporation (NVDA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


KYMRNVDADifference
Sharpe ratioReturn per unit of total volatility

+1.66

Sortino ratioReturn per unit of downside risk

+2.39

Omega ratioGain probability vs. loss probability

1.42

1.13

+0.28

Calmar ratioReturn relative to maximum drawdown

5.37

1.17

+4.20

Martin ratioReturn relative to average drawdown

12.76

2.53

+10.23

KYMR vs. NVDA - Sharpe Ratio Comparison

The current KYMR Sharpe Ratio is 2.32, which is higher than the NVDA Sharpe Ratio of 0.66. The chart below compares the historical Sharpe Ratios of KYMR and NVDA, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

KYMR vs. NVDA - Drawdown Comparison

The maximum KYMR drawdown since its inception was -87.51%, roughly equal to the maximum NVDA drawdown of -89.72%. Use the drawdown chart below to compare losses from any high point for KYMR and NVDA.


Loading charts...

Drawdown Indicators


KYMRNVDADifference

Max Drawdown

Largest peak-to-trough decline

-87.51%

-89.72%

+2.21%

Max Drawdown (1Y)

Largest decline over 1 year

-27.74%

-20.21%

-7.53%

Max Drawdown (3Y)

Largest decline over 3 years

-59.83%

-36.88%

-22.95%

Max Drawdown (5Y)

Largest decline over 5 years

-83.54%

-66.34%

-17.20%

Max Drawdown (10Y)

Largest decline over 10 years

-66.34%

Current Drawdown

Current decline from peak

-7.50%

-13.56%

+6.06%

Average Drawdown

Average peak-to-trough decline

-48.81%

-36.12%

-12.69%

Ulcer Index

Depth and duration of drawdowns from previous peaks

11.66%

9.35%

+2.31%

Volatility

KYMR vs. NVDA - Volatility Comparison

Kymera Therapeutics, Inc. (KYMR) has a higher volatility of 23.57% compared to NVIDIA Corporation (NVDA) at 10.82%. This indicates that KYMR's price experiences larger fluctuations and is considered to be riskier than NVDA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


KYMRNVDADifference

Volatility (1M)

Calculated over the trailing 1-month period

23.57%

10.82%

+12.75%

Volatility (6M)

Calculated over the trailing 6-month period

36.25%

27.37%

+8.88%

Volatility (1Y)

Calculated over the trailing 1-year period

64.26%

35.74%

+28.52%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

72.95%

51.87%

+21.08%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

75.47%

49.90%

+25.57%

Dividends

KYMR vs. NVDA - Dividend Comparison

KYMR has not paid dividends to shareholders, while NVDA's dividend yield for the trailing twelve months is around 0.14%.


PositionTTM20252024202320222021202020192018201720162015
KYMR
Kymera Therapeutics, Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
NVDA
NVIDIA Corporation
0.14%0.02%0.03%0.03%0.11%0.05%0.12%0.27%0.46%0.29%0.45%1.20%

Financials

KYMR vs. NVDA - Financials Comparison

This section allows you to compare key financial metrics between Kymera Therapeutics, Inc. and NVIDIA Corporation. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0020.00B40.00B60.00B80.00BJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025AprilJulyOctober2026April
34.37M
81.62B
(KYMR) Total Revenue
(NVDA) Total Revenue
Values in USD except per share items

Frequently Asked Questions


KYMR and NVDA have a correlation of 0.14, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

KYMR has higher volatility (23.57%) compared to NVDA (10.82%). In terms of maximum drawdown, KYMR dropped -87.51% vs NVDA's -89.72%.

KYMR currently has the higher Sharpe Ratio (2.32 vs 0.66), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for KYMR and NVDA

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer